FICHe: Final Intermediate Report - Europa · FP7 – 632913 CONFIDENTIAL FICHe – Final intermediate Report 5 3.2 Core of the report for the period: Project objectives, work progress

FICHe: Final Intermediate Report

Grant Agreement number: 632913

Project acronym: FICHe

Project title: Future Internet Challenge eHealth

Funding Scheme: Combination of Collaborative Project and Coordination and Support Action

Date of latest version of Annex I against which the assessment will be made:

DOW FICHe (632913) 2015-10-01.pdf

Period covered: from December 1st 2015 to June 30th 2016

Name, title and organisation of the scientific representative of the project's coordinator1: Satu Väinämö, FICHe Project Coordinator, University of Oulu (OUL)

Tel: + 358 50 4370 978

E-mail: [email protected]

Project website2 address: www.f6s.com/FICHe http://digitalhealthstartup.eu

1 Usually the contact person of the coordinator as specified in Art. 8.1. of the Grant Agreement. 2 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format

at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm logo of the 7th

FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned.

mailto:[email protected]

http://www.f6s.com/FICHe

http://digitalhealthstartup.eu/

http://europa.eu/abc/symbols/emblem/index_en.htm

http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos

FP7 – 632913 CONFIDENTIAL FICHe – Final intermediate Report

2

Table of Contents 3.1 Publishable summary ............................................................................................................ 3

3.2 Core of the report for the period: Project objectives, work progress and achievements,

project management ........................................................................................................................ 5

3.2.1 Project objectives for the period ................................................................................... 6

3.2.2 Work progress and achievements during the period .................................................... 6

3.2.2.1 WP 5 – Challenge Phase 3 ............................................................................................. 6

3.2.2.1.1 Support: coaching, webinars and events, matchmaking ........................................... 7

Mentoring and Expert Coaching............................................................................................ 8

Webinars and events ............................................................................................................. 8

Matchmaking ....................................................................................................................... 10

3.2.2.1.2 Field trials (living labs).............................................................................................. 11

3.2.2.1.3 Collecting all prototypes, plans, reports and strategies .......................................... 13

3.2.2.2 WP 6 – Promotion and dissemination ........................................................................ 14

3.2.2.2.1 Promotion ................................................................................................................ 14

3.2.2.2.2 Closing Event ............................................................................................................ 15

3.2.3 Project management during the period ...................................................................... 18

3.3 Deliverables and milestones tables ..................................................................................... 23


3

3.1 Publishable summary

The aim of the Future Internet CHallenge eHealth (FICHe) project is to challenge European small and

mid-sized enterprises (SME) and startups that develop innovative applications and businesses in the

eHealth market building upon the available FIWARE technology, i.e. FIWARE generic enablers,

specific enablers and/or domain specific platforms (www.fiware.org ). The most promising and

innovative proposals complying the requirements of each phase have been selected by an

Independent Review Committee (IRC) to continue to the next phases. 80 teams entered the first

phase with grant of 15.000€, 40 continued with 50.000€, and 20 finalists entered the third and last

phase, receiving 152.000€. In addition to direct funding SMEs and startups have received technical

training and business coaching, and have tested their solutions in the field labs (Living labs).

Figure 1: The process of FICHe accelerator project

During the final period FICHe Phase3 was finalized. Top 20 companies further developed their PoC

into a field lab tested market ready prototype, while elaborating their business model and go-to-

market strategy.

During the final period the main achievements have been:

- Support the testing of prototypes in the Living Labs

- Individual online coaching

- Arranging webinars and events to Top20 companies and FIWARE community

- Matchmaking SMEs with experts

- Arranging the closing event

Important outcome of the FICHe project will be the reinforcement of the directly benefited SMEs as

world-class companies, capable of successfully competing at the global level. Reaching critical mass

by the easier access to international funding and markets, will boost their growth while reducing

market fragmentation in Europe. New business niches and untapped opportunities for SMEs and

startups will be discovered through the involvement of end users of the eHealth market. These


4

newly niches will in turn not only promote job creation within the eHealth market but also stimulate

the economy supporting eHealth SMEs.

FICHe project Coordinator is University of Oulu from Finland. Other partners are: 1. Finland: City of Oulu (BusinessOulu) 2. The Netherlands: Dutch eHealth Fund Management BV, Stichting Digitalezorg.nl, Stichting

ZorgInc, Stichting Amsterdam Economic Board and TNO 3. Spain: TIC BioMed, FFIS de la region de Murcia

www.f6s.com/fiche , http://digitalhealthstartup.eu/

http://www.f6s.com/fiche

http://digitalhealthstartup.eu/


5

3.2 Core of the report for the period:

Project objectives, work progress and achievements, project management

According to the Grant Agreement, consortium partners’ identifier, name, short name and country are as follow:

No Participants Organisation name Acronym Country

1 OULUN YLIOPISTO OUL Finland

2 DUTCH EHEALTH FUND MANAGEMENT BV DEH The Netherlands

3 TICBIOMED TECNOLOGIAS DE LA INFORMACION PARA LA SALUD EN LA REGION DE MURCIA ASOCIACION

TBM Spain

4 FUNDACION PARA LA FORMACION E NVESTIGACION SANITARIAS DE LA REGION E MURCIA

- Linked 3rd party: Servicio Murciano de Salud

SMS Spain

5 OULUN KAUPUNKI BOU Finland

6 STICHTING DIGITALEZORG.NL SDZ The Netherlands

7 ZORGINC. ZIC The Netherlands

8 STICHTING AMSTERDAM ECONOMIC BOARD AEB The Netherlands

9 NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK - TNO

TNO The Netherlands

Figure 2: FICHe team and Top 20 companies in Health 2.0, Europa conference

This report describes the activities and the achievements of FICHe project during the following period: from December 1st, 2015 to June 30th, 2016.


6

3.2.1 Project objectives for the period

In this period the main objective was the finalizing of the phase 3 and arranging FICHe closing event.

Objectives are described more detailed below:

- Webinars: Access to Grants, CE certification and FDA approval, How to fund your business

and how to engage with VCs & Angel investors

- Individual online coaching

- Matchmaking SMEs with experts, Top companies/key public players, VCs/Angels, Investors

- Support of prototype testing in the Living Labs

- FICHe closing event in Health 2.0 in Barcelona

3.2.2 Work progress and achievements during the period

In this section, the overview of the process of the work and main achievements are described. The

exception is WP1 – Project management activities that will be described in the section 3.2.3 Project

management during the period.

The FICHe work plan is divided to six (6) work packages: Project management, Pitch Event, Phase1,

Phase2, Phase3 and Dissemination. The overall work plan is as follows:

Figure 3: Work plan

During the final period work was carried out in WP1, 5 and 6 work packages.

3.2.2.1 WP 5 – Challenge Phase 3

Objectives of the WP5 (Challenge Phase3) completed in the reporting period were to support

companies to develop their Proof of Concept (PoC) into market-ready working prototype built on

FIWARE technology, to test the prototype with end users and further develop their business model,

go-to-market strategy, funding plan and team setting.


7

Tasks of the WP5 included an individual coaching on business, eHealth and user involvement fields

as well as technical support of FIWARE technology.

3.2.2.1.1 Support: coaching, webinars and events, matchmaking

FICHe provided the tailored support services for the participants. Based on interviews with

European accelerator programs and incubators combined with lessons of the Lean Start-up method

framework was developed. The framework of the phase 3 illustrated below (Figure 4: Framework -

Phase 3 approach) was used to structure the process while still maintaining flexibility as all

participants had different challenges at different times. The phase 3 was divided into three periods:

Preparation, Action and Results.

The action period started already in October and continued until the end of February 2016. In this

period the participants focused on six different development areas: Living Lab, Go-to-Market,

Business model, Funding, FIWARE, and Team. FICHe provided the tailored support for the

participants in the areas of: mentoring, expert coaching, webinars, events and matchmaking. In the

third period participants focused on delivering the defined end deliverables.

Figure 4: Framework - Phase 3 approach


8

A questionnaire was launched in the end of the Phase3 in order to get feedback from all FICHe start-

ups and SMEs. All Top 20 companies answered the questionnaire, however only one Phase1/2

company answered the questionnaire.

Mentoring and Expert Coaching

The mentors continued to act as ‘the hub to knowledge’ for the participants. The mentoring

activities included regular online one-to-one meetings. During the subsequent meetings,

information about the activities and reviews about the living labs took place, as well as reminders

for the FICHe webinars and events, making sure that the companies were aware and able to

participate in. Furthermore, the mentor coached on the activities that had to be done in Phase3 and

monitored the progress against DOW. In total there were 19 mentors during Phase3. The specific

coaching was also provided through a community of experts. There were altogether 29 expert

coaches.

Based on the result of the questionnaire answered by Top 20 SMEs and start-ups the mentoring and

expert coaching were seen very important and useful. The support variated based on the needs of

the company. Most important value of mentoring by top 20: Focus (9) 45%, Experience (10) 50%,

Network (5) 25%, Other 1 (5%). The main topics mentioned by companies were: the mentors and

experts shared their knowledge, network and experience on both eHealth business and technical

perspective as well as made sure that companies kept on track and finished the acceleration with a

market ready product.

“The most important value from mentors is that they have helped to think in different thinks that are important for our product and business, and in the daily work you don't think.” (Source: FICHe questionnaire for Top 20 companies, April 2016) “New ways we didn't know for our business development and those related with the living lab in the hospital processes and interests.” (Source: FICHe questionnaire for Top 20 companies, April 2016) “Have an insight in the investors mind was really helpful.” (Source: FICHe questionnaire for Top 20 companies, April 2016)

Webinars and events

Participants were interviewed by the mentors regarding the most important topics of which they

would like to gain more expertise. Based on the results the following Webinars were organised in

this period:

Access to (European) Grants, 8/12/2016 (1 hour) The webinar of European Grants was facilitated by Lian van Amerongen link and Cecile ten Kate

both are very experienced in this field. The main focus was to inform the SME’s about the

https://nl.linkedin.com/in/lianvanamerongen


9

different European Subsidies, the deadlines and the requirements to apply. 14 out of 20

companies participated to the Webinar.

CE certification and FDA approval, 17/12/2016 (1,5 hour) For the CE and FDA webinar two experts were selected: Erik Vollebregt, who is a very

experienced lawyer in this field, has worked with a broad range of start-ups and corporates

within the field of eHealth as well as is an advisor for the government, and Fokko Wierenga, a

senior expert on medical technology, who is involved in bringing medical technology to the

market and supporting companies with CE marking. The main focus was to share experts’

knowledge and to provide documents and links about CE and FDA. 16 out of 20 companies

participated in the Webinar.

How to fund your business and how to engage Angel & Venture Capitalist, February 26, 2016 (1,5 hour) Ville Heikkinen, partner at Butterfly (VC) and Xavier Palomer Ripoll CEO of Psious (FICHE top20)

shared their knowledge and experience in funding an eHealth business from the perspective of

a Venture Capitalist and a SME. FICHe SME Psious finished a series A funding round in 2015 >MIO

1.05 EUR. 10 out of 20 companies participated to the Webinar.

During the last period altogether 3 events were organised. The events (2) for Top 20 participants

focused on the FICHe specific topics e.g. team and networking, while FIWARE community event was

focused on community building. The community events were organised in cooperation with other

FIWARE accelerator programs. The events were as follows:

FICHe meet-up: FICHe Intermediate event, January 22, 2016 Amsterdam, The Netherlands

Topic: Successfully communicating with different stakeholders, customers, investors, and

suppliers. What is the story of your company? Why should they buy, invest or work with you?

The training was about building the ‘human story’ which is essential to your health product or

service. 8 out of 20 companies participated to the event.

Figure 5: Amsterdam FICHe meet-up

FICHe Closing event during Health 2.0 Congress: May 10-12, 2016 Barcelona, Spain link

Topic: Showcase the working prototype built on FIWARE technology to investors and other

eHealth key players. Moreover, meet other participants and stakeholders. More info (Closing

event). All 20 companies participated to the event.

https://nl.linkedin.com/in/erikvollebregt

https://www.linkedin.com/profile/view?id=AAkAAAKt5IcBxa_LirGI9yIkihzPTvo32oeIgxs&authType=NAME_SEARCH&authToken=2Ei1&locale=en_US&trk=tyah&trkInfo=clickedVertical%3Amynetwork%2CclickedEntityId%3A44950663%2CauthType%3ANAME_SEARCH%2Cidx%3A1-1-1%2CtarId%3A1452505645038%2Ctas%3Afokko

https://www.linkedin.com/profile/view?id=AAkAAAKt5IcBxa_LirGI9yIkihzPTvo32oeIgxs&authType=NAME_SEARCH&authToken=2Ei1&locale=en_US&trk=tyah&trkInfo=clickedVertical%3Amynetwork%2CclickedEntityId%3A44950663%2CauthType%3ANAME_SEARCH%2Cidx%3A1-1-1%2CtarId%3A1452505645038%2Ctas%3Afokko

http://www.health2con.com/events/conferences/health-2-0-europe-2016/http:/www.health2con.com/events/conferences/health-2-0-europe-2016/


10

Figure 6: Exhibition floor in FICHe closing event

Mobile World Congress: Feb 22-25, 2016 Barcelona, Spain link

This was FIWARE community building event. FICHe partnership with ECHAlliance in order to

facilitate the participation of the FIWARE SMEs at the Digital Health & Wellness Summit @

Mobile World Congress 2016.

Based on the questionnaire the webinars and events were useful. The results were as follows:

Figure 7: Overall satisfaction of the webinars and events

(Source: FICHe questionnaire for Top 20 companies, April 2016)

Matchmaking

FICHe provided different kind of matchmaking possibilities to the companies: 1) Matching

participant with Top Companies/Key public players in eHealth sector for Partnership or access to

important first buyer, 2) Matching participants with VC/angels looking for investment opportunities

within eHealth, and 3) Investor meetup in FICHe Closing event. The consortium facilitated the

matchmaking. Examples of matchmaking in this period are described in table below.

8,2

7,4

7,6

8,9

9,0

7,6

webinar EU Grants

fund your business

CE/FDA approval eHealth

Murcia living-lab kick-off

Intermediate Session A'dam

1-on-1 Pitch deck support

Ratings of webinars and events

http://www.mobileworldcongress.com/

http://www.mobileworldcongress.com/


11

Table 1: Matchmaking examples in the fourth period

FICHe initiator Company To

Ms. Steensma Scyfer Venture Capitalists Max Niederhofer from Sunstone Capital

and Ville Heikkinen from Butterfly

MS. Steensma PLUX Lian van Amerongen (Senior consultant business

development Life Sciences and Healthcare at PNO

Consultant). They decided to work together to apply for SME

Instrument.

Mrs. Anna

Sachinopoulou

Ourpath Mr. Karppinen (Expert of behavioural change) from the

University of Oulu

Mr. W. de Jager PX

Heathcare

The largest hospital group specialized in Cancer. PX

Healthcare and the group of hospital have signed a contract

to collaborate.

Furthermore two FICHe companies (NeuroAtHome and Umanick) were selected to FIWARE VIP

program. They were selected among ~1 000 FIWARE companies. One of the main benefits been in

the VIP program was the VIP bootcamp, which content was tailored for the participants. There

participants modified their pitch decks and reserved individual coaching, met investors and

expanded their network.

3.2.2.1.2 Field trials (living labs)

During the final period the participants performed their field test activities either in their own living

labs or living labs provided by the consortium partners. AEB, OUL and SMS supported participants

in various ways:

For the business to business approach in Amsterdam it was essential to find the right healthcare

organizations and hospitals for a living lab. The mentors brought in their experience, network and

connecting skills to be as effective as possible for the companies. Issues were discussed frequently

between the Dutch mentors. According to one company, Clinical Graphic, mentorship has helped

them in overcoming collaboration challenges. One of the companies set up a living lab at a care

institution in Amsterdam and other companies got advice regarding setting up field tests in other

living labs close to Amsterdam. Scyfer and Clinical Graphics worked together in a Living Lab for one

hospital after advice by their mentor. The results were good and they continued collaboration and

found their potential launching customer, Bergman Clinics in the Netherlands.


12

OULLabs user experience (UX) specialist from University of Oulu carried out three UX evaluations of

the solutions of FICHe participants mentored by Finnish partners (OUL and BOU). The evaluations

were performed in January – February 2016. Another more comprehensive test case has been

planned to be conducted in a real healthcare environment involving medical specialist and patients

after FICHe project, however all the planning and preparations were done in February – May 2016.

Murcia Living Lab continued hosting the seven (7) living lab test projects from FICHe participants

mentored by Spanish partners (TBM, FFIS, SMS). During the living lab testing the functionality and

analysis of the solutions were improved as in many cases associated clinical mentors evaluated the

solutions and value creation processes aiming to solve issues after the end of the project, and also

determine which solutions would be worth of continuing with. More than 25 clinical professionals

have worked directly or indirectly with testing the solutions. Professional mentoring has led the

solutions being tested in Murcia better adapt to the demands of market needs. From the beginning,

SMS made all possible resources available to companies and their solutions, both in terms of their

clinical knowledge in each of the areas, processes or solutions in order to engage proven

professionals.

As a great result from the point of view of SMS, 5 of the 7 solutions are considering the continuation

of living lab, which will allow them to further improve their capabilities with the help of permanent

real environment and receive advice by the professionals of each area. Some of the companies also

are at the starting point of a final future acquisition after this period.

Another important value gathered through Living Lab has been the media coverage that has been

given to the solutions being tested. Visibility was great on various radio and television channels, and

especially the participation of the Minister of Regional Health, Murcia helped to disseminate FICHe

in various health forums in the country of national and international importance., One of the

solutions has been awarded as the best solution in the world in the field of RFID technology in

Orlando, USA by the prestigious magazine RFID journal, which was also noticed in media.

The companies valued the outcome of the living lab testing of their solutions in a real environment

as significantly higher than expected, all agreed that living lab testing has given a great value to their

solutions and work as a reference for future marketing and sales. The living lab helped to detect

problems, fix technical bugs, and optimize the solution as well to improve the product. Moreover,

the living lab kept the pressure on the development of the solution. For example, some companies

made major improvements based on the usability and reliability findings. 7 of the 20 companies felt

that the living lab phase was a true reality check which brought them back on the track of the patient

and market needs. Nevertheless, due to the short time, some SMEs, hadn’t got the opportunity to

incorporate user feedback from the living lab into their products, although had the chance to make

several iterations of improvements based on feedback of internal testers or friends. For some SMEs

living lab also gave the opportunity to learn a lot about the public health sector and its technology.


13

“It has helped us on detecting problems on our solution and fixing technical bugs. We have

learned a lot about the public health sector and its technology.” (Source: FICHe questionnaire for Top 20 companies, April 2016)

“We realized that the problem articulated by clinicians in the earlier phases was the wrong

one and we had to change direction to solve the underlying problem” (Source: FICHe questionnaire for Top 20 companies, April 2016)

“Living lab had a very large impact on the product especially around product reliability and

usability, and required several major product iterations.” (Source: FICHe questionnaire for Top 20 companies, April 2016)

Almost all top 20 companies will continue to use the living lab approach in their product and solution

development. This will allow them to further improve their capabilities with the help of real

environment and receive advice by the professionals and patients. As a result of the Murcia living

labs, some of the companies also are at the starting point of a final future acquisition.

“Living Lab has been essential for us for fixing our solution. We will continue using living

labs to continue testing and proving the benefits of our solution in the future, with the same

technology as well as with new developments.” (Source: FICHe questionnaire for Top 20 companies, April 2016)

“The Living Lab process (user testing and refinement) is essential in any development

process, we will be continuing to do this in the future.” (Source: FICHe questionnaire for Top 20 companies, April 2016)

“Absolutely critical. We will always involve users throughout the development process.” (Source: FICHe questionnaire for Top 20 companies, April 2016)

3.2.2.1.3 Collecting all prototypes, plans, reports and strategies

In the January 2016 the Mid-term review was held. In the review the progress of all 20 participants

against the DOW was reviewed. The mentors were the main reviewers, as they had followed the

progress of the participant monthly basis. In addition, FIWARE expert reviewed the progress of the

implementation of the FIWARE technology. Together mentors and FIWARE experts proposed the

approval or rejection of the review to the consortium. All 20 companies passed the review.

In March, 2016, the submission form on F6S was opened to the 20 participants. All participants were

asked to upload to F6S the six obligatory deliverables of Phase3:

- FIWARE implementation document

- Field test report(s)

- Revised Business model


14

- Go-to-strategy materials

- Demo-video of the working prototype

- Investor Pitch Deck

- Funding plan including clear exit strategy

End deliverables review took place in April 2016. The mentors, FIWARE experts and representative

of University of Oulu reviewed the end deliverables of the all 20participants. . Together reviewers

proposed the approval or rejection of the review to the consortium. 16 companies passed the

review on the first time. 4 participants needed to enhance their documents as well as clarify their

implementation of FIWARE technology. In the second review round the end deliverables of the last

four participants were approved.

As a result all the 20 companies were able to showcase their solutions in the Health 2.0 conference

in Barcelona, Spain.

3.2.2.2 WP 6 – Promotion and dissemination

The main objectives of the final period were to promote FICHe project and the companies, to

organize a closing event as well as to share information among project participants.

In order to achieve the objectives, multiple activities were organized during this period. Start-ups

and their milestones were promoted via multiple media channels, several events and meetings were

leveraged to get attention to the startups, active matchmaking between investors and partners was

organized, a press release and FICHe portfolio was published, and finally the closing event was

organized in Barcelona.

3.2.2.2.1 Promotion

During the phase 3 the main communication channels continued to be Twitter and the web portal.

In this period, Twitter was used to promote events, activities and milestones. Several articles were

also published on the website. The website, F6S, Mobilize.io, and media channels of the partners

were used to promote the closing event. Especially in Spain there was a lot of exposure created via

radio, newspapers and television.

To promote the results of FICHe and the startups, a press release for the closing event was issued.

This press release was published by multiple press and websites. The portfolio, a 50+ page booklet

containing information on the startups, project partners and FIWARE was also made. The booklet is

still available in digital form: http://bit.ly/23vODh9

To gain more attention to the startups, the project partners leveraged multiple events. In Spain

during several meetings and events (e.g. Mobile World Congress and Health2.0) FICHe startups were

able to present on stage and discuss issues. In The Netherlands PX Healthcare, Scyfer, Betawerk,

Psious, and NeuroAtHome joined the Startup2Scaleup event organized by project partner

http://bit.ly/23vODh9


15

Digitalezorg.nl, together with the Ministry of Health. They were able to meet with 280 investors,

partners and policymakers from The Netherlands. The Dutch startups were also invited to the high

profile investors’ dinner. In Finland Netictech together with E3 project (E-health services

Everywhere and for Everyone https://www.celticplus.eu/project-e3/ ) showcased MedVC to their

main customers: doctors, medical experts and decision makers.

During the closing event as well as during the Startup2Scaleup event, the FICHe startups were

exposed to digital health investors. At the closing event 30+ investors joined, at Startup2Scaleup 15

digital health investors joined.

The Amsterdam Economic Board took advantage of the health ecosystem in the Amsterdam

Metropolitan Area to communicate the impact and results of on the Board website, and through

the Board’s Twitter and LinkedIn accounts. In addition, two of the finalists were taken up in a two

pitch events during dedicated sessions in the eHealth week 2016. The eHealth week 2016 was also

used to further disseminate FICHe results, to incorporate FICHe experience in a Dutch national

eHealth fund.

FICHe participated also in the INFORSALUD 2016 event, which offered a unique opportunity for

health professionals, researchers, industry, and public sector to expose and share their demands

and needs, and to discuss how to proceed in improving the quality and continuity of care with the

help of ICT. For FICHe the event was a good opportunity to showcase the project methodology of

Living Lab and the developed solutions.

3.2.2.2.2 Closing Event

The closing event of FICHe was organised in conjunction with Health 2.0 Europe in Barcelona in

order to leverage all available resources and count with key stakeholders in digital health that will

attend the event as well as provide networking opportunities for companies. The event is one of the

leading digital health startup and investor event.

The event attracted 600+ delegates and over 30 digital health investors from across Europe. During

the promotion of the event a lot of attention was raised for FICHe as partner and the co-hosting as

closing event.

https://www.celticplus.eu/project-e3/


16

During the event the Top 20 companies showcased their solution and usage of FIWARE technology

into their products in the exhibition space, pitched in front of the investors and presented their

solution on the main stage.

The first day was dedicated to meet the investors and pitch in front of them. This EC2VC meeting

was organized by the GET project. European startups could apply for pitching and out of over 100

applications, three FICHe startups were selected: HealthApp, MintLabs and UMANICK. All three

companies pitched in front of investors and received valuable feedback.

Figure 8: EC2VC event in Health 2.0

The second and third day of the event was organized as a conference with many speakers and

network opportunities. As FICHe partnered with this conference, we were able to offer the twenty

companies premium exhibition space. The 20 booths were positioned close to the drinks and lunch

area, which assured that there was enough traffic and attention for the companies. Many startups


17

commented that they had opportunity to talk to potential partners and customers in the event. The

FICHe portfolio booklet made for the event was spread among the conference delegates.

Figure 9: Exhibition area

Startups had also an opportunity to apply to present their solution on main stage throughout the

conference. From the FICHe startups HealthApp, MedBravo, MindMyths, MintLabs and MySphera

were selected to present. Their presentations were scattered throughout the two days and

presented in between in-depth sessions to maximize attention.

Figure 10: Opening ceremony (left) and Medbravo presenting their solution in the main stage (right)

In connection with the event, FICHe organized a celebration networking drinks. This social event

was not only about celebrating the end of FICHe, but also provide the opportunity to meet

interesting new partners. With over 125 people joining the networking drinks, many startups

commented that it was a success.

Figure 11: FICHe networking event


18

3.2.3 Project management during the period

The main management activities during the period have been

- Project coordination - Contracts and Sub-Grant Agreements - Management of the Independent Review Committee - Co-operation with FI-PPP projects

In this reporting period, the deliverables were the following:

- D1.5: Final report - D5.2: Collection of 20 prototypes, including validated business models and investor pitch

deck - D5.3: Collection of meeting reports and attendee list - D6.4 Content Database - D6.5 Closing Event - D6.6 Monitoring report

The milestones in the reporting period were:

- M8: Closing event According to Description of the Work (Annex I of Grant agreement FICHe (Contract 632913)) all

deliverables and the last milestone M8 were achieved on schedule.

Overall, resources have been used slightly more than planned in the end of month 25. Almost 184

person months, which is 9 PMs more than planned, has been used across all work packages. The

main reasons were an intense coaching in the phase 3 and strong support in Living Lab field testing.

However, the costs remained within total budget because work was partly done by staff with lower

PM rate.

Monthly project meetings procedure has been continued as in the first period for sharing

information and to discuss relevant issues. Action point procedure and their accomplishment have

been monitored and supported by the Coordinator. A16 meeting was in Milan in January. Project

coordinator Ms. Satu Väinämö (OUL) attended the meeting as FICHe representative. In addition the

Coordinator has participated in A16 telcos and FIWARE expert Bas Kotterink (TNO) has participated

in FI-PPP steering meeting in May as FICHe representative. General Assembly was held on February

16-17 2016 in Murcia. Altogether 12 participants attended the meeting. All consortium members

were present except one who participated via skype. This was the fourth face-to-face meeting with

consortium. The general aim of the GA meeting was to discuss the phase3, the closing event and

finalizing the project. Additionally other current project issues were discussed.


19

Table 2: List of meetings

Meeting Date Venue

December Project meeting December 14, 2015 Online

FI-PPP steering board meeting December 14, 2015 Online

FICHe Executive board meeting December 18, 2015 Online

January Project meeting January 11, 2016 Online

FICHe mid-term consensus meeting January 14, 2016 Online

A16 telco January 19, 2016 Online

A16 meeting January 28 -29, 2016 Milan

FI-PPP steering board meeting January 29, 2016 Milan

General Assembly February 16-17, 2016 Murcia

FICHe periodic review March 1, 2016 Online

A16 telco March 10, 2016 Online

March project meeting March 14, 2016 Online

April project meeting April 11, 2016 Online

A16 telco April 18, 2016 Online

FICHe end deliverables meeting April 19, 2016 Online

FI-PPP steering board meeting May 04, 2016 Online

June project meeting June 6, 2016 Online

A16 meeting June 8-10, 2016 Tallinn

During the period all the communication has been centralized through the Coordinator. The

Coordinator has kept on continuous communication with Project Officer regarding the progress of

the project and any issues needing clarification or advice. No major disruption by conflicts of interest

happened in this period.

The final periodic report was prepared in cooperation with all partners. The report consisted of

activities of P19-P25.


20

Sub-Grant Agreement and payments

The review meetings were held: the mid-term and the end deliverables reviews. After the mid-term

review the second payment was made. The third and the last payment was made after the approval

of the end deliverables and financial documents.

The sub-grants have been paid in two payments during the reporting period: - Phase3 (1st payment): total 35 800 EUR to 1 SME in December - Phase3 (2nd payment): total 0,6 MEUR to 20 SMEs in January - Phase3 (3rd payment): total 1,796 MEUR to 20 SMEs in May/June

In total 6 235 424 euros was paid to the companies as a Sub grants during the FICHe. In the table 2 the payments per company is described.

Table 3: Total amount of payment/company

Company Phase 1/2/3 Amount of sub grant paid

17rabbits Phase1 € 15 000,00

Andaman7 (Manex) Phase1 € 15 000,00

Bloei NL BV Phase1 € 15 000,00

BlueActio Health Phase1 € 15 000,00

Braci Ltd. Phase1 € 13 322,12

Creoir Oy Phase1 € 15 000,00

CROSSING THE MIRROR, S.A. Phase1 € 15 000,00

Dotsoft S.A. Phase1 € 15 000,00

E-ASSYST Phase1 € 15 000,00

EigenZorg Phase1 € 14 575,72

E-sites B.V. Phase1 € 15 000,00

EUROB CREATIVE SLNE Phase1 € 15 000,00

FIVE FLAMES MOBILE Phase1 € 15 000,00

Fullduplex Phase1 € 14 999,25

FysioPal Phase1 € 15 000,00

H&M srl Phase1 € 15 000,00

Hapticore Phase1 € 15 000,00

IG.COM Srl Phase1 € 14 847,73

IncreaseTime SA Phase1 € 14 697,83

Inmote MT BV Phase1 € 15 000,00

INNOCV SOLUTIONS, S.L. Phase1 € 13 631,01

Introme Ltd. Phase1 € 15 000,00

ITIOX TECNOLOGICA S.L. Phase1 € 15 000,00

ITTI Ltd. Phase1 € 15 000,00

Karisma Kidz Phase1 € 15 000,00

LabCup Limited Phase1 € 15 000,00

Metack Maciej Kompf Phase1 € 15 000,00

My People Care Phase1 € 15 000,00

MYSD LTD Phase1 € 15 000,00


21

NewHealth Collective BV Phase1 € 15 000,00

Oppifi Oy Phase1 € 14 965,15

Oy ProWellness Ltd. Phase1 € 15 000,00

Planet Media Studio Phase1 € 15 000,00

Real Time Multiple Biomedical Sensor Phase1 € 15 000,00

RenalHelp Phase1 € 15 000,00

Sentimoto Ltd Phase1 € 14 635,85

SocialDiabetes Phase1 € 15 000,00

WT, Wellness Telecom, S.L. Phase1 € 15 000,00

XIM Ltd Phase1 € 15 000,00

AC-Gen Reading Life S.L. Phase2 € 65 000,00

Blue On Shop GmbH Phase2 € 61 368,72

Descansare Sleep Lab, S.L Phase2 € 65 000,00

digital worx GmbH Phase2 € 65 000,00

Egriot srl Phase2 € 65 000,00

Fabulyzer Sensors Phase2 € 15 000,00

Horus Technology Srls Phase2 € 65 000,00

Hygea Phase2 € 65 000,00

iEHR.eu Roman Radomski Phase2 € 65 000,00

LIME / LIME Technology Phase2 € 64 644,99

Magicbox Television and Interactive Services SL Phase2 € 65 000,00

Mint Labs S.L. Phase2 € 63 712,97

MotionChart Phase2 € 65 000,00

NEURODIGITAL TECHNOLOGIES SL Phase2 € 65 000,00

PentaTech Sp. z o.o. Phase2 € 63 603,95

Pflegeprotokoll APP GmbH Phase2 € 65 000,00

Synappz BV Phase2 € 65 000,00

Taniwa Soluciones, S.L. Phase2 € 65 000,00

TheMarketsTrust Phase2 € 65 000,00

Trendalyze Decisions Ltd Phase2 € 65 000,00

Andiamo Phase3 € 220 800,00

Betawerk BV Phase3 € 220 677,51

Clinical Graphics B.V. Phase3 € 220 800,00

Healthapp, S.L. Phase3 € 220 800,00

Ideable Solutions Phase3 € 220 800,00

Inbiolab B.V. Phase3 € 220 800,00

InDigital Systems Ltd Phase3 € 220 800,00

Medbravo Phase3 € 220 800,00

Mind Myths Limited Phase3 € 220 800,00

MYSphera Phase3 € 220 800,00

NETICTECH Phase3 € 220 800,00

NeuroAtHome Phase3 € 220 677,06

Our Path Ltd Phase3 € 220 800,00

Oviva AG Phase3 € 220 800,00


22

Pantavision (Panatomy) Phase3 € 220 800,00

PLUX - Wireless Biosignals, S.A. Phase3 € 220 800,00

Psico Smart Apps S.L. Phase3 € 220 296,38

Px HealthCare B.V. Phase3 € 216 967,94

Scyfer BV Phase3 € 220 800,00

UMANICK Technologies, S.L. Phase3 € 220 800,00

Cooperation with FI-PPP projects

Co-operation with other accelerators has been conducted mainly through A16 (FIWARE accelerator

projects) meetings, FIWARE Basecamp, email and Skype calls. Different project issues have been

discussed and consulted by other accelerators or supporting parties such as FI-Business and FICORE.

FICORE has been continuously supporting SMEs regarding FIWARE issues. The Coordinator also

participated to the FI-PPP Steering Board meetings.


23

3.3 Deliverables and milestones tables

Table 4: Deliverables

TABLE 1. DELIVERABLES

Del. no.

Deliverable name Version WP no. Lead beneficiary

Nature

Dissemination

level3

Delivery date from Annex I (proj month)

Actual / Forecast delivery date

Dd/mm/yyyy

Status

No submitted/

Submitted

Comments

3 PU = Public

PP = Restricted to other programme participants (including the Commission Services).

RE = Restricted to a group specified by the consortium (including the Commission Services).

CO = Confidential, only for members of the consortium (including the Commission Services).

Make sure that you are using the correct following label when your project has classified deliverables.

EU restricted = Classified with the mention of the classification level restricted "EU Restricted"

EU confidential = Classified with the mention of the classification level confidential " EU Confidential "

EU secret = Classified with the mention of the classification level secret "EU Secret "


24

D1.1 Intermediate Report1

1 OUL R CO P6 30/01/2015 yes


1 OUL R CO P9 14/04/2015 yes


1 OUL R CO P13 31/08/2015 yes


1 OUL R PU P18 26/01/2016

D1.5 Final Report 1 OUL R PU P25 30/06/2016 Yes

D2.1 Pitch Event 2 SDZ O PU P4 16/09/2014 no

D2.2 List of 500 registered visitors and viewers

2 SDZ R PU P4 1/11/2014 yes List contains:

Registered participants of the pitch events, registered participants of the webinar and the unregistered number of viewers to the recorded events. Total number of 1200+.

D2.3 List of 200 application ideas

2 SDZ R PU P4 01/11/2014 yes The list contains 308 submitted applications

D2.4 List of 80 challengers that will enter the challenge + review report

2 DEH R CO P6 30/12/2014 yes

D2.5 List of 40 challengers that will continue to phase2 + review report

2 DEH R CO P10 01/04/2015 yes


25

D2.6 List of 20 challengers that will continue to phase3 + review report

2 DEH R CO P15 23/07/2015 yes

D3.1 Enrolment Briefing report

3 BOU R PP P6 16/01/2015 yes

D3.2 3-boot-camps 3 BOU R PP P8 07/02/2015 yes

D3.3 Collection of 80 challengers applications to be reviewed

3 BOU R CO P8 28/02/2015 yes


4 TBM R PP P10 14/04/2015 Yes

D4.2 5 trainings for the Challengers

4 TBM R PP P13 17/07/2015 Yes

D4.3 Collection of meeting reports and attendee list

4 TBM R CO P13 17/07/2015 Yes

D4.4 Collection of 40 concepts to be reviewed

4 TBM R CO P13 30/06/2015 Yes


5 ZIC R PP P15 4/12/2015 Yes

D5.2 Collection of 20 prototypes, including validated business models and investor pitch deck

5 ZIC R CO P24 31/05/2016 Yes Videos of prototypes


26

D5.3 Collection of meeting reports and attendee list

5 ZIC R PP P24 31/05/2016 Yes

D6.1 Stakeholder Mapping in 15+ MS

6 SDZ R PU P2 1/09/2014 yes The mapping contains at least 1 key stakeholder in each MS + additional stakeholders, regarding reaching the SMEs and startups.

D6.2 Promotion campaign, incl. list of promoting partners

6 SDZ O PU P4 1/11/2014 no Collection of promoting partners, articles, tweets and events

D6.3 Website, incl. other dissemination tools

6 SDZ O PU P4 1/09/2014 no F6S.com was used as main website and open call management platform. Twitter is used as main comms. platform.

D6.4 Content database 6 SDZ O PU P25 30/06/2016 no

D6.5 Closing Event 6 SDZ O PU P24 10-12 /05/2016

no

D6.6 Monitoring report 6 SDZ R CO P25 30/06/2016 Yes


27

Table 5: Milestones

TABLE 2. MILESTONES

Milestone no.

Milestone name

Work package no

Lead beneficiary

Delivery date from Annex I dd/mm/yyyy

Achieved Yes/No

Actual / Forecast achievement date dd/mm/yyyy

Comments

MS1 Kick-off Meeting

1 SDZ P1 Yes 03/06/2014

MS2 Start promotion campaign

6 SDZ P1 Yes 12/06/2014

MS3 Pitch Event 2 SDZ P4 Yes 16/09/2014

MS4 Opening Challenge

2 SDZ P4 Yes 15/09/2014

MS5 Start the 1st phase of the Challenge

3 BOU P6 Yes 30/12/2014 Due to one month delay in Open call phase.

See section: Project management

MS6 Start the 2nd phase of the Challenge

4 TBM P10 Yes 07/04/2015 Due to one month delay in Open call phase.

See section: Project management

MS7 Start the 3rd phase of the Challenge

5 ZIC P15 Yes 23/07/2015

MS8 Closing Event

6 SDZ P24 Yes 10-12/05/2016

Documents

FICHe: Final Intermediate Report - Europa · FP7 – 632913 CONFIDENTIAL FICHe – Final intermediate Report 5 3.2 Core of the report for the period: Project objectives, work progress